title: Osteoporosis in patients referred for lung transplantation.
abstract: OBJECTIVE
  Osteoporosis may significantly impair the final result of lung transplantation. The purpose of study is to determine the prevalence of osteoporosis with the regard to risk factors for osteoporosis in patients awaiting lung transplantation.
  
  
  METHODS
  We determined bone mineral density (BMD) in 48 patients (12 with idiopathic pulmonary fibrosis (IPF), 15 with other form idiopathic interstitial pneumonia (IIP), 5 with sarcoidosis and 16 with COPD) referred for lung transplantation (LT). BMD was performed on lumbar spine (LS), total hip (TH), and femoral neck (FN). Osteoporosis risk factors were analyzed with the consideration to principal diagnosis, lung function tests (FVC, FEV1) and mobility (6 MWT; six minute walking test).
  
  
  RESULTS
  In osteoporosis group (50% of study population) the most affected was LS (mean T-score -3 ±1), with higher steroid consumption (cumulative steroid dose 40 ±28), lower FVC, FEV1 and mobility (6 MWT: 285 m) than in patients without osteoporosis. COPD patients presented the lowest BMD with the highest cumulative steroid dose (csd/kg: 0.6 ±0.6), lowest FEV1 (21 ±15% pred.) and 6 MWT (279 m). In patients with the lowest steroid consumption (IPF) the best results of BMD and FVC, FEV1 and 6 MWT were observed. No relation was found between BMD and sex and age in study group.
  
  
  CONCLUSIONS
  Osteoporosis is very common in patients referred for lung transplantation, especially among COPD candidates. Steroid consumption is the mean risk factor. Therefore, early diagnosis and prevention of osteoporosis in lung transplant candidates should receive high priority.
authors.affiliation: Department of. Lung Diseases and Tuberculosis, Silesian Medical University, Zabrze, Poland. darekjdr@poczta.onet.pl
authors.forename: D
authors.initials: D
authors.lastname: Jastrzebski
authors.forename: W
authors.initials: W
authors.lastname: Lutogniewska
authors.forename: M
authors.initials: M
authors.lastname: Ochman
authors.forename: A
authors.initials: A
authors.lastname: Margas
authors.forename: K
authors.initials: K
authors.lastname: Kowalski
authors.forename: J
authors.initials: J
authors.lastname: Wyrwol
authors.forename: B
authors.initials: B
authors.lastname: Ksiazek
authors.forename: J
authors.initials: J
authors.lastname: Wojarski
authors.forename: S
authors.initials: S
authors.lastname: Zeglen
authors.forename: D
authors.initials: D
authors.lastname: Ziora
authors.forename: J
authors.initials: J
authors.lastname: Kozielski
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D000367:Age Factors; D000368:Aged; D015519:Bone Density; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology*; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy; D012307:Risk Factors
chemical_list: D000305:Adrenal Cortex Hormones